TRDA (Entrada Therapeutics) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Apr. 12, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Entrada Therapeutics Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Entrada Therapeutics's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Entrada Therapeutics's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Entrada Therapeutics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entrada Therapeutics's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Entrada Therapeutics (NAS:TRDA) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Entrada Therapeutics Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Entrada Therapeutics's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Entrada Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entrada Therapeutics Inc (NAS:TRDA) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Design Center Place, Suite 17-500, Boston, MA, USA, 02210

Website

https://www.entradatx.com

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Executives

Kory James Wentworth	officer: Chief Financial Officer	6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210
Mpm Bioventures 2018, L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Natarajan Sethuraman	officer: Chief Scientific Officer	6 TIDE STREET, BOSTON MA 02210
Nathan J Dowden	officer: Chief Operating Officer	6 TIDE STREET, BOSTON MA 02210
Dipal Doshi	director, officer: President and CEO	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Peter S Kim	director	ONE MERCK DRIVE, P.O. BOX 100, WHITEHOUSE STATION X1 08889
Nerissa Kreher	officer: Chief Medical Officer	C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Gina Chapman	director	C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403
Bernhardt G Zeiher	director	ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210
Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Todd Foley	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Felix Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
John F Crowley	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512